Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products. Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.

Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. It focuses on developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications. The firm is developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target, truncated O-glycans on MUC16. The company was founded in 1996 and is headquartered in Edmonton, Canada.

Ethicon Endo-Surgery, Inc. manufactures surgical devices and equipments. Its products include the ENDOPATH XCEL access system, CONTOUR curved cutter stapler, HARMONIC ultrasonic cutting and coagulation surgical devices and the MAMMOTOME breast biopsy system. The company was founded in 1992 and is headquartered in Cincinnati, OH.

Alpheus Medical, Inc. is a company headquartered in North Oakdale, MN. The firm develops novel sonodynamic therapy platform that targets solid body cancers. It was founded by Vijay Agarwal, who is the current CEO of the firm.\nThe company says this about itself: Alpheus Medical, Inc, is a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers. The company's lead product utilizes a novel, non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma. Alpheus Medical's work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology and with support from the American Cancer Society and the National Brain Tumor Society. The therapy is currently in early clinical stage use and is not yet commercially available.

Guangzhou Yisi Biotechnology Development Co., Ltd., established on 2018-09-29, Business scope includes medical research and experimental development;Biomedical Technology Research;Regenerative Medicine Anti-aging Research Services;Medical technology research and development;drug development;Pharmaceutical Research Services

Sono Medical is a biomedical technology company that focuses on R&D, design, production and sales of edical equipment in the field of cardiovascular diseases.

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

Dalian University of Technology Industrial Investment Co., Ltd., established on 1988-06-20, Business scope includes,Manage the school's operating assets and the equity of the school's foreign investment;Realtor;property management;Domestic general trade.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

CranioVation has developed an innovative solution to treat aggressive brain tumors using light delivered via a minimally invasive device, allowing patients to avoid undergoing invasive brain surgery. CranioVation has solved the problem by inventing a device that is able to treat even those tumors located deep within the brain without the need for complex, dangerous, and often disfiguring surgery.

Guangzhou Yisi Bioengineering Technology Co., Ltd., established on 2007-11-30, Business scope includes technical promotion of research results of health science projects;Sales of products produced by the company(Except for projects prohibited by national laws and regulations;Products involving licensed operation need to obtain a license before they can be operated);Biomedical Technology Research(human stem cells,Except for genetic diagnosis and treatment technology);Medical Technology Consulting,communication service;Biotechnology Transfer Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Health Sciences Program Research Transfer;Materials Science Research,technology development;Biotechnology Development Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Nutrition and Health Consulting Services;Health Sciences Program Research,to develop;Medical technology promotion service;Medical technology transfer service;Biotechnology Extension Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Consulting,communication service(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);

A spin-off of Roswell Park Cancer Institute (RPCI), Photolitec is a new life-sciences company developing photosensitizing compounds for image-guided photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI's Photodynamic Therapy Center. The compounds that Photolitec is working to commercialize were developed primarily by Ravindra Pandey, Ph.D. while at RPCI. Dr. Pandey is a Distinguished Member of the PDT Center and Director of Pharmaceutical Chemistry at RPCI, and is the founder and Chief Scientific Officer of Photolitec.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

The Scientific Group (Pty) Ltd. supplies diagnostic laboratory equipment and consumables to Pathology laboratories. The firm operates through the following divisions: Clinical Division, Export Division, Biosciences Divisions, Medical Division, and Service Division. The Clinical Division has a core structure servicing state and private pathology laboratories in the form of clinical analyzers and diagnostic reagents. The Export Division that focuses on overall healthcare advice and service, with on and off-site training providing support to regions of Sub-Saharan Africa. The Biosciences Division caters for more specialized molecular biology and biotechnology equipment consumables and reagents for all research and molecular diagnostic applications. The Medical Division provides corrective products for the cardiology market along with hospital requirements such as patient monitoring apparatus, theatre lights, and imaging equipment. The Service division provides fully trained service technicians and engineers on a 24-hour basis and call centre assistance. The company was founded in 1983 and is headquartered in Johannesburg, South Africa.

Suzhou Gena Biotechnology Co., Ltd., established on 2016-11-16, Business scope includes biotechnology,Technology development in the field of biomedicine and medical devices,technical consulting,technology transfer,Technical Services;Research and development of computer hardware and software,Sales and technical service;Self-operated and agent import and export business of various commodities and technologies;Instrumentation and accessories,Sales of laboratory consumables;electronic product,teaching facility,Mechanical and electrical product sales and technical services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

GE Healthcare AS markets contrast agent for x-ray, ultrasound, Magnetic Resonance Imaging, and radiopharmaceuticals for clinicians to predict, diagnose, inform, and treat diseases. The company was founded on September 07, 1981 and it is headquartered in Oslo, Norway.

Innovation Ulster Limited (IUL) is a wholly owned knowledge and technology venturing company of Ulster University. Investment funds are provided by IUL for the commercial development of Ulster's research, to ensure the diffusion of knowledge into the private sector and promote the industry attractiveness of its Intellectual Property. IUL Investment Policy goals are to: - create an entrepreneurial environment in the University that encourages and rewards the generation of new inventions and knowledge, including educational materials, by staff and students - facilitate the transfer of new commercially and socially important inventions and knowledge to society - maximise the University's commercial impact IUL aims to maximise the commercial and economic impact of Ulster's research, and achieve a long-term rate of return that in real terms shall equal or exceed the rate of spending on its investments, and to do so with an acceptable level of risk.